Conmed (CNMD) Cash from Financing Activities (2010 - 2026)

Conmed's Cash from Financing Activities history runs 17 years deep, the most recent figure standing at -$22.6 million for Q1 2026.

• Quarterly Cash from Financing Activities rose 20.58% year-over-year to -$22.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$130.0 million (up 19.96% YoY) and the FY2025 annual result came in at -$135.8 million, up 10.05% from the prior year.
• Cash from Financing Activities was -$22.6 million for Q1 2026 at Conmed, up from -$37.4 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $159.1 million in Q2 2022 and bottomed at -$58.8 million in Q4 2023.
• A 5-year average of -$11.5 million and a median of -$26.5 million in 2025 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities soared 820.17% — and 2023, when it sank 610.34%.
• Conmed's Cash from Financing Activities stood at $11.5 million in 2022, then sank by 610.34% to -$58.8 million in 2023, then advanced by 13.1% to -$51.1 million in 2024, then increased by 26.83% to -$37.4 million in 2025, then jumped by 39.65% to -$22.6 million in 2026.
• Business Quant data shows CNMD's Cash from Financing Activities at -$22.6 million in Q1 2026, -$37.4 million in Q4 2025, and -$43.5 million in Q3 2025.